脂代谢紊乱与动脉粥样硬化课件

Cardiovasculardiseaseistheleadingcause

ofdeathamongadultsworldwide(1996)Coronarydisease 7.2millionCancer 6.3Cerebrovasculardisease 4.6Acutelowerrespiratorytractinfections 3.9Tuberculosis 3.0COPD(chronicobstructivepulmonarydisease) 2.9Diarrhea(includingdysentery) 2.5Malaria 2.1AIDS 1.5HepatitisB 1.2Cardiovasculardiseaseisthe1Coronarymortality:

alarmingworldwideforecastsCoronarymortality:

alarmingw2Atherosclerosis:

amultifactorialdiseaseAtherosclerosis:

amultifactor3MainriskfactorsforcoronaryheartdiseaseMainriskfactorsforcoronary4Globalprojectionsforthediabetesepidemic:

1995-2010Globalprojectionsforthedia5AtherosclerosisAtherosclerosis6Arterialwall:

structureandfunctionArterialwall:

structureandf7Differentstagesofatheroscleroticplaque

developmentDifferentstagesofatheroscle8Vascularendotheliummodification

inatherosclerosisVascularendotheliummodificat9Plaqueformation

1—Fattystreak

Plaqueformation

1—Fattystr10Plaqueformation

2—Fibrouscap

Plaqueformation

2—Fibrousc11Plaqueformation

3—Lipidcore

Plaqueformation

3—Lipidcor12Fromplaquetothrombosis,keyevent:

plaqueruptureFromplaquetothrombosis,key13Lipidcoreconstitution

ActivatedmacrophagesaccumulatelipidsLipidcoreconstitution

Activa14Lipidcoreconstitution

LDLoxidationLipidcoreconstitution

LDLox15Parietalvascularinflammation

TheactivatedmacrophageproducesinflammatorycytokinesParietalvascularinflammation16

Parietalvascularinflammation

NFkBactionintheinflammationprocess

Parietalvascularinflammatio17DiabetesandatherosclerosisDiabetesandatherosclerosis18TobaccoandatherosclerosisTobaccoandatherosclerosis19DyslipidemiaandatherosclerosisDyslipidemiaandatheroscleros20HTN,hemodynamicfactorandatheroclerosisHTN,hemodynamicfactorandat21Howtoreduceplaqueformation

InterventiononriskfactorsHowtoreduceplaqueformation22HowtoreducetheriskofplaqueruptureHowtoreducetheriskofplaq23HowtoreducetheriskofthrombosisHowtoreducetheriskofthro24~10%Weightloss=~30%Visceral

adiposetissueloss~10%Weightloss=~30%Viscer25CharacteristicsofanunstableplaqueCharacteristicsofanunstable26Plaquevulnerabilityfactors

IntrinsicfactorsPlaquevulnerabilityfactors

27ModificationofextrinsicvulnerabilityfactorsModificationofextrinsicvuln28

Plaquerupture

Themainreleasingfactors

Plaquerupture

Themainrele29ClassificationoflipidsandlipoproteinsClassificationoflipidsandl30CharacteristicsoflipoproteinsCharacteristicsoflipoprotein31Triglyceride-richlipoproteins:

size,structureandcompositionTriglyceride-richlipoproteins32DigestionandmetabolismofdietaryfatDigestionandmetabolismofdi33HDLmetabolismandreversecholesteroltransportHDLmetabolismandreversecho34Cholesteroleffluxandreversecholesterol

transportismodulatedbytworeceptorsCholesteroleffluxandreverse35AtherogenicityofsmalldenseLDLAtherogenicityofsmalldense36Sizeandapolipoproteincompositionarethemainfactorsdeterminingatherogenicityoftriglyceride-richparticlesSizeandapolipoproteincompos37Sizeandapolipoproteincompositionarethemainfactorsdeterminingatherogenicityoftriglyceride-richparticlesSizeandapolipoproteincompos38ApoC-IIImodulatesVLDLApoC-IIImodulatesVLDL39ApoC-IIIinapoBparticlesisatherogenicApoC-IIIinapoBparticlesi40RelationshipbetweenapoC-IIIinapoB

containinglipoproteinsandatherogenicityRelationshipbetweenapoC-III41PROCAMStudy

MI-IncidenceaccordingtoLDL-cholesterolandtriglyceridesPROCAMStudy

MI-Incidenceacco42PROCAMStudy

CHDriskaccordingtoLDL-CandTG

increasedTGconfersraisedCHDriskatalllevelsofLDL-CPROCAMStudy

CHDriskaccordin43HDL:

ananti-atherogeniclipoproteinHDL:

ananti-atherogeniclipop44HDLmetabolism:

5keygenes

HDLmetabolism:

5keygenes45HDL:

apoAI-richparticlesHDL:

apoAI-richparticles46ApoA-IprotectsagainstatherosclerosisApoA-Iprotectsagainstather47ApoA-IIprotectsagainstatherosclerosis

ThehumanapoA-IItransgenicmousemodelApoA-IIprotectsagainstathe48Genesandenvironmentintype2diabetes

andatherosclerosisGenesandenvironmentintype49PimaIndians

ThriftygenesPimaIndians

Thriftygenes50AboriginalCanadiansOji-CreeAboriginalCanadiansOji-Cree51Obesity,type2diabetes,atherosclerosisObesity,type2diabetes,athe52TheMetabolicSyndromeTheMetabolicSyndrome53Visceralobesityisassociatedwithacluster

ofmetabolicabnormalitiesVisceralobesityisassociated54TheatherogenictriadTheatherogenictriad55PROCAMStudy:

MI-IncidenceaccordingtoLDL-cholesterolandtriglyceridesPROCAMStudy:

MI-Incidenceacc5670%ofmenwithCHDhadalowHDL≤44mg/dL

FraminghamMaleOffspring35-5470%ofmenwithCHDhadalow57Obesity,type2diabetes,lipidmetabolism

ThekeyroleofthetranscriptionalfactorsPPARsObesity,type2diabetes,lipi58

PPARadiscoveryelucidates

mechanismofactionoffibrates

PPARadiscoveryelucidates

me59ThedifferentPPARsubtypesThedifferentPPARsubtypes60PPARa:

atranscriptionfactorPPARa:

atranscriptionfactor61PPARa:

transcriptionalactivationintwostagesPPARa:

transcriptionalactivat62PPARa:

transcriptionalactivationintwostages

PPARa:

transcriptionalactivat63TranscriptionalactivationbyPPARaTranscriptionalactivationby64

PPARs:

regulationoflipoproteinmetabolismbyPPARa

PPARs:

regulationoflipoprot65PPARaactivatorslowersmalldenseLDLPPARaactivatorslowersmalld66AnapolipoproteinidentifiedAnapolipoproteinidentified67Plasmatriglycerideandcholesterollevels

forhumanapoA-VtransgenicmicePlasmatriglycerideandcholes68Plasmatriglycerideandcholesterollevels

forapoA-VknockoutmicePlasmatriglycerideandcholes69AllelefrequenciesforSNP3according

toplasmatriglyceridelevelsAllelefrequenciesforSNP3a70PPARaactivatorsinduceapoA-V

geneexpressionPPARaactivatorsinduceapoA-71PPARaactivateshumanapoA-V

transcriptionthroughtwoPPREsPPARaactivateshumanapoA-V

72

PPARa:apoA-l,apoA-ll,LPL,

ABCA-1andSR-BIexpression

PPARa:apoA-l,apoA-ll,LPL73PPARaactivatorsinduceABCA-1geneexpression

inhumanmacrophagesPPARaactivatorsinduceABCA-174PPARaactivatorsinducecholesterolefflux

fromhumanmacrophagesPPARaactivatorsinducecholes75CLA-1/SR-BIproteinmaypromotecholesterol

removalfromperipheralcellsCLA-1/SR-BIproteinmaypromot76CLA-1expressionisregulatedbyPPARaactivators

indifferentiatedhumanmacrophagesCLA-1expressionisregulated77PPARaactivatorsinducecholesterolefflux

andreversecholesteroltransportPPARaactivatorsinducecholes78PPARsinthevascularwallPPARsinthevascularwall79MechanismsoftransrepressionbyPPARaMechanismsoftransrepression80ThetranscriptionfactorNFkB:

akeyroleintheinflammatoryresponseThetranscriptionfactorNFkB:81ModelofNFkBsignalpathwayinhibition

byPPARaactivatorsModelofNFkBsignalpathwayi82PPARaactivatedbyfibratesinhibitsIL-1b

inducedexpressionofCOX-2inSMCPPARaactivatedbyfibratesin83

FenofibratereducesplasmaIL-6

inpatientswithCAD

FenofibratereducesplasmaIL84

FenofibratelowersplasmaCRP

inpatientswithCAD

FenofibratelowersplasmaCRP85PPARaactivatorsreduceadhesionmolecule

productionbyinterferingwithNFkBPPARaactivatorsreduceadhesi86PPARactivatorsreduceendothelin-1production

byinterferingwithAP-1transcriptionfactorPPARactivatorsreduceendothe87PPARaactivatorsinhibitthrombininducedET-1secretioninhumanmacro-andmicrovascularendothelialcellsPPARaactivatorsinhibitthrom88PPARaactivatorsreducetissuefactorproductionby

interferingwithNFkBandAP-1transcriptionfactorsPPARaactivatorsreducetissue89PPARaactivatedbyfibratesnegatively

regulatesfibrinogen-bexpressionPPARaactivatedbyfibratesne90Statins

Molecularmechanismsofaction

SREBPfeedbackcontrol

Statins

Molecularmechanismso91SREBP*regulatestheLDLreceptor

Three-stepactivationprocessSREBP*regulatestheLDLrecep92CommonpropertiesofPPARaactivators

andstatins

Parietalvasculareffects

CommonpropertiesofPPARaact93StatinsandPPARaactivators,similareffects

Similareffector,PPARa?

StatinsandPPARaactivators,94StatinsinducePPARaactivityStatinsinducePPARaactivity95HumanapoA-ImRNAisinduced

bystatinsinadose-dependentmannerHumanapoA-ImRNAisinduced

96StatinsactonapoA-ImRNA

expressionatthetranscriptionallevel

InhibitionbyactinomycinD

StatinsactonapoA-ImRNA

e97StatineffectonapoA-Isynthesis

isrelatedtoitsmodeofaction

Inhibitionbymevalonate

StatineffectonapoA-Isynth98StatinsandPPARaactivators

increasehumanapoA-IgeneexpressionStatinsandPPARaactivators

i99Simvastaticacidreducesinduced

LPSMMP9secretionSimvastaticacidreducesinduc100Parietalvasculareffectsofstatins(1)

EndothelialcellsParietalvasculareffectsofs101Parietalvasculareffectsofstatins(2)

Monocytes,macrophagesParietalvasculareffectsofs102PPARaactivatorsactonthemainfactors

involvedintheonsetofatherosclerosisPPARaactivatorsactonthema103

VA-HIT

VA-HIT104VA-HITcontVA-HITcont105

DAIS

DAIS106

DAIScont

DAIScont107

HHS

HHS108HHScontHHScont109

4S

4S110

4Scont

4Scont111

CARE

CARE112

CAREcont

CAREcont113

WOSCOPS

WOSCOPS114

WOSCOPScont

WOSCOPScont115

LIPID

LIPID116

LIPIDcont

LIPIDcont117

AFCAPS/TexCAPS

AFCAPS/TexCAPS118

AFCAPS/TexCAPScont

AFCAPS/TexCAPScont119

AVERT

AVERT120

AVERTcont

AVERTcont121

HPS

HPS122

HPScont

HPScont123

NCEPguidelines

NCEPguidelines124

NCEPguidelinescont

NCEPguidelinescont125

NCEPguidelinescont

NCEPguidelinescont126

NCEPguidelinescont

NCEPguidelinescont127

AHA/ACCguidelines

AHA/ACCguidelines128

ADAguidelines

ADAguidelines129

ADAguidelinescont

ADAguidelinescont130

LipidmanagementforprimarypreventionofCHD

inadults–ILIBrecommendations

Lipidmanagementforprimary131

LipidmanagementforsecondarypreventionofCHD

inadults–ILIBrecommendations

Lipidmanagementforsecondar132

LipidmanagementforsecondarypreventionofCHD

inadultswithdiabetesmellitus–ILIBrecommendations

Lipidmanagementforsecondar133

AbbreviationslistAS AtherosclerosisBL BaselineBMI BodyMassIndexBP BloodPressureCABG CoronaryArteryBypassGraftCAD CoronaryArteryDiseaseCARE CholesterolandRecurrentEventsCE CholesterolEsterCERP CholesterolEffluxRegulatoryProteinCETP CholesterolEsterTransferProteinCHD CoronaryHeartDiseaseCHF CongestiveHeartFailureChol Cholesterol COX-2 Cyclo-oxygenase-2CRP CReactiveProteinCV CardiovascularCVD CardiovascularDiseaseDM DiabetesMellitusECTIM StudyEtudeCasTemoinsdeIífarctusduMyocardeER EndoplasmicReticulumET-1 Endothelin-1GE GlycerolEstersHDL-C High-DensityLipoproteinCholesterolHL HepaticLipaseHT HypertensionICAM IntercellularAdhesionMoleculeIL InterleukinLCAT LecithinCholesterolAcetylTransferaseLDL-C Low-DensityLipoproteinCholesterolLPL LipoproteinLipasemg/d MilligramsperDaymg/dL MilligramsperDeciliterMI MyocardialInfarctionNFkB NuclearFactor

BNS NotSignificantPAI-1 PlasminogenActivatorInhibitorType1 Plc PlaceboPPARs PeroxisomeProliferator-ActivatedReceptorsPROCAM ProspectiveCardiovascularMunsterStudyPPRE ResponsiveElementPTCA PercutaneousTransluminalCoronaryAngiographyRXR RetinoidXReceptorSig SignificantSREBP SterolRegulatoryElementBindingProteinTC TotalCholesterolTF TissueFactorTG TriglycerideTNF TumorNecrosisFactorUAP UnstableAnginaPectorisVCAM VascularCellAdhesionMoleculevs VersusWHR WaistHipRatio

AbbreviationslistAS Atheros134

ReferencelistFigure1.WHOpressreleasebasedontheDirectorGeneralreport,1997.Figure2.MurrayCJLandLopezAD.Evidence-basedhealthpolicy—lessonsfromtheGlobalBurdenofDiseaseStudy.Science1996;274:740–743Figure4.WengerNK.Genderdifferencesincoronaryriskfactorsandriskinterventions.In:AtherosclerosisRiskFactorsandTreatments,2ndedition(Ed.WilsonPWF),p214,1996.Figure7.DiCorletoPE,etal.Vascularendothelium.In:AtherosclerosisandCoronaryArtery

Diseasevol.1,(Eds.Fuster,Ross,Topor).Lippincott-RavenPublishers,p387,1996.Figure9.DiCorleto,PE,etal.Vascularendothelium.InAtherosclerosisandCoronaryArtery

Disease,vol.1.(Eds.Fuster,Ross,Topor).Lippincott-RavenPublishers,p387,1996.Figures14,15,17,18and24.RainesEW,etal.Theroleofmacrophages.In:AtherosclerosisandCoronaryArteryDisease(Eds.Fuster,Ross,Topor).Lippincott-RavenPublishers,p539–551,1996.Figures14,21,35and36.FalkE,etal.Pathogenesisandplaquedisruption.In:AtherosclerosisandCoronaryArteryDisease(Eds.Fuster,Ross,Topor).Lippincott-RavenPublishers,p491–507,1996.Figure26.AronsonD,etal.Diabetesandobesity.In:AtherosclerosisandCoronaryArtery

Disease(Eds.Fuster,Ross,Topor).Lippincott-RavenPublishers,p327,1996.Figure27.StaffordRS,etal.Cigarettesmokingandatherosclerosis.In:Atherosclerosisand

CoronaryArteryDisease(Eds.Fuster,Ross,Topor).Lippincott-RavenPublishers,p303,1996.Figure28.ChisolmGM,etal.Oxidizedlipoproteinsandatherosclerosis.In:Atherosclerosisand

CoronaryArteryDisease(Eds.Fuster,Ross,Topor).Lippincott-RavenPublishers,1996.Figure33and62.AdaptedfromDespresJP,LemieuxIandPrud’hommeD.Treatmentofobesity:needtofocusonhighriskabdominallyobesepatients.BMJ2001;322;716–720.Figure34.DavisMJetal.BritHeartJ1993;69;377.Figures35and36.FalkE.Whydoplaquesrupture?Circulation1992;86(supplIII);30–42.Figures42.FruchartJC.Physiologyoflipidsandlipoproteins.PrevCardiol1999;11;119–125.Figures43.SingarajeRR,FievetC,CastroG,JamesER,HennuyerN,CleeSM,BissadaN,ChoyJC,FruchartJC,McManusBM,StaelsB,HaydenMR.IncreasedABCA-1activityprotectsagainstatherosclerosisJClinInvest2001;110;35–42.Figures44.RaspeE,DuezH,GervoisP,FievetC,FruchartJC,BesnardS,MarianiJ,TedguiA,StaelsB.TranscriptionalregulationofapolipoproteinC-111geneexpressionbytheorphannuclearreceptorRORa.JBiolChem2001;276;2865–2871.Figures46.FruchartJC,ClaveyV,LucG,DallongevilleB,StaelsB,AuwerxJ.ApolipoproteinC-111animportantplayerinlipoproteinmetabolism.Proc.X11InternationalSymposium‘Drug

affectinglipidmetabolism:riskfactorsandfuturedirections’.Eds.GottoM,PaolettiR,SmithLC,etal.KluwerAcademicPublishers,1996,631–638.Figure47.deSilvaHV,LauerSJ,WangJetal.OverexpressionofhumanapolipoproteinC-IIIintransgenicmiceresultsinanaccumulationofapolipoproteinB48remnantsthatiscorrectedbyexcessapolipoproteinE.JBiolChem1994;269;2324–2335.Figure48.LucG,FievetC,ArveilerDEvansAE,BardJM,CambienF,FruchartJC,DucimetiereP.ApolipoproteinsC-IIIandEinapoB-andnon-apoB-containinglipoproteinsintwopopulationsatcontrastingriskformyocardialinfarction:theECTIMstudy.EtudeCasTemoinssur‘InfarctusduMyocarde’.JLipidRes1996;37;508–517.Figure49and50.SacksFM,AlaupovicP,MoyeLA,etal.VLDL,apolipoproteinsB,CIII,andE,andriskofrecurrentcoronaryeventsintheCholesterolandRecurrentEvents(CARE)trial.Circulation2000;102;1886–1892.

ReferencelistFigure1.WHOp135

ReferencelistcontFigures55.DuvergerN,KruthH,EmmanuelF,CaillaudJM,VigliettaC,CastroG,TailleuxA,FievetC,FruchartJC,HoudebineLM,DenefleP.Inhibitionofatherosclerosisdevelopmentincholesterol-fedhumanapolipoproteinA-1transgenicrabbits.Circulation1996;94;713–717.Figure56.TailleuxA,BoulyM,LucG,CastroG,CaillardJM,HennuyerN,PoulainP,FruchartJC,DuvergerN,DenefleP.Decreasedsusceptibilitytodiet-inducedatherosclerosisinhumanapolipoproteinA-IItransgenicmice.ArteriosclerThrombVascBiol2000;11;2453–2458.Figure58.KnowlerWC,PettittDJandSaadMF,etal.ObesityinthePrimasIndians.Itsmagnitudeandrelationshipwithdiabetes.AmJClinNutr1991;53;s1543–1551.Figure59.HegeleRA.Genesandenvironmentintype2diabetesandatherosclerosis.In:AboriginalCanadian,CurrentAtherosclerosisReports2002;3;216–221.Figure63.LamarcheB,TchernofA,MauriegeP,etal.FastinginsulinandapolipoproteinBlevelsandlow-densitylipoproteinparticlesizeasriskfactorsforischemicheartdisease.JAMA1998;279;1955–1961.Figure73.FruchartJC.Arenuclearfactorstheultimatetargetsofdrugsaffectinglipidmetabolism?CurrentAtherosclerosisReports2000;2;353–354.Figure75,76,77and78.PennancchioLA,OliverM,HubacekJA,CohenJC,CoxDR,FruchartJC,KraussRM,RubinEM.AnapolipoproteininfluencingtriglyceridesinhumansandMicerevealedbycomparativesequencing.Science2001;294;169–173.Figures82and83.ChinettiG,LestavelS,BocherV,RemaleyAT,NeveB,PinedaTorraI,TeissierE,MinnichA,JayeM,DuvergerN,BrewerHB,FruchartJC,ClaveyV,StaelsB.PPARaandPPARgactivatorsinducecholesterolremovalfromhumanmacrophagefoamcellsthroughstimulationoftheABCA-1pathway.NatureMedicine2001;7;53–58.Figure84and85.ChinettiG,BaguidiG,GriglioS,MallatZ,AntonucciM,PoulainP,ChapmanJ,FruchartJC,TedguiJ,Najib-FruchartJ,StaelsB.CLA-1/SR-B1isexpressedinatherosclerosislesionmacrophagesandregulatedbyactivatorsofperoxisomeproliferator-activatedreceptors(PPARs).Circulation2000;101;2411–2417.Figure86.FruchartJC.PPARaactivationandHDLmetabolism.AmJCardiol2001;88supp.;24N–29N.Figure87,88,89,